NOVA Stock Price and Chart — SWB:NOVA

Key facts today

Novo Nordisk will restructure its board on November 14, with Chairman Helge Lund and six directors resigning. The company faces a 56% stock price drop amid market share losses.

Novo Nordisk is advocating to maintain Medicaid coverage for its obesity drug Wegovy as several U.S. states consider cuts due to rising costs, highlighting its role in long-term healthcare savings.

Novo Nordisk A/S has scheduled an Extraordinary General Meeting (EGM) to elect new members to its Board of Directors.

Analyze the impact Analyze the impact

About Novo Nordisk A/S Class B

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as NOVA.